Retatrutide Side Effects: What the Studies Found
Phase 2 and Phase 3 studies found four common Retatrutide side effects. They were nausea, vomiting, diarrhea, and constipation. The same problems occur with GLP-1 drugs, which copy one hunger hormone.
Most problems did not become severe. They came up most while the amount rose. Serious health problems were uncommon.
At lower doses, the rate was much like placebo, a dummy shot. The sections below cover Phase 2 papers and early Phase 3 TRIUMPH-1 results. The study length still can't settle lifetime risk.
What Retatrutide safety checks found
Jastreboff's 2023 Phase 2 weight study found mostly stomach and bowel trouble. Larger doses brought more cases. Most eased after the amount stopped rising [1]. The course over time may matter more than one day's symptoms.
Rosenstock's 2023 Phase 2 diabetes study found those problems in 35%, or 67/190 people. No Phase 2 group had dangerously low blood sugar. Serious problems were rare. At lower doses, their rate was much like placebo [2].
A 2025 review combined three Phase 2 studies with 878 patients. The studies put people in groups by chance. They found no major warning for the thyroid, pancreas, or heart [20]. Stomach and bowel trouble remained the main side effect. These Phase 2 studies can't give a lifetime answer.
Lilly's 2025 Phase 3 TRIUMPH-1 news covered all three dose groups. Leaving rates were 4.1% on 4 mg and 6.9% on 9 mg. The rate was 11.3% on 12 mg and 4.9% with placebo. Stomach and bowel trouble caused most exits [17]. All three groups passed the planned weight-loss test. The Phase 2 record had been shorter.
When Retatrutide side effects began and eased
Phase 2 problems were most common in weeks 1–8. That was when the study amount rose. Some began within hours of the first shot. Most eased after the amount stayed level [10]. The rates changed over time.
A review combined the Phase 2 results. It compared each problem with placebo, the dummy shot. Nausea was 2.69× to 4.27× more common. The range comes from different study amounts. Vomiting was 4.62× to 8.98× more common.
Diarrhea was 1.64× to 2.51× more common. Constipation was 4.17× to 4.41× more common [10]. Most problems stayed mild or moderate.
At 12 mg, up to about 60% reported nausea while the amount rose. The Phase 2 rate fell after the amount stayed level. Study guides named a slower rise and small, low-fat meals. Those steps were meant to ease trouble [10].
What problems the Retatrutide studies counted
The combined Phase 2 results put nausea as high as 60% on 12 mg. Diarrhea affected 15–33%, vomiting 21–26%, and constipation 10–20%. Higher-dose groups had more gut trouble while the amount rose [10]. The ranges reflect different groups and amounts.
Less common findings included a short rise in a liver blood test. That test can rise when liver cells are irritated. Resting hearts beat 2–4 more times each minute. Related hunger drugs can do that too. Researchers are still asking what a lasting rise means [20].
In rodents, the third hormone action lowered blood protein parts and broke down muscle [14]. Those are lab findings in animals, not people. Human Phase 2 body scans didn't show more lean-mass loss than other weight drugs [6]. Lean mass includes muscle and other tissue besides fat. That was another Phase 2 question.
What Phase 2 and Phase 3 found about serious harm
Serious health problems were rare in Phase 2. Pancreatitis, or swelling of the pancreas, didn't rise clearly above placebo. Rodent studies had found changes in certain thyroid cells.
Human Phase 2 blood tests didn't find those changes. A thyroid blood test kept people with a high result out of TRIUMPH groups. That test can flag trouble in certain thyroid cells. Since those people didn't join, the results may not cover their risk. Phase 3 thyroid checks continue [20].
In Phase 3 TRIUMPH-1, 11.3% left the 12 mg group. Stomach and bowel trouble caused most exits. Serious problems stayed rare across the groups. All three dose groups passed the planned weight-loss tests [5][17]. Those were Phase 2 findings. The short record can't settle your long-term risk.
TRIUMPH-3 is still checking heart health. No result had shown changes in heart attacks, strokes, or heart-related deaths by May 2026.
What Retatrutide did not settle about serious harm
Phase 2's chief concern was gut trouble. It rose with the dose and caused most exits. Serious problems were uncommon. The short study found no clear rise over placebo in pancreatitis, thyroid cancer, or heart harm [20]. Short studies can't settle what might happen years later.
Phase 2 reviews carried warnings from related drugs that copy one hunger hormone. Those warnings cover the thyroid and gallbladder. They don't prove retatrutide caused either problem.
Rodents had thyroid changes, but Phase 2 human blood tests did not. Phase 3 studies still watch both problems. After related drugs stop, about 75.6% of lost weight may return [18]. That figure came from several related drugs, not retatrutide alone.
What study staff did from week 1 onward
Study amounts rose in small steps to limit stomach trouble. Study guides also named small meals and enough water. High-fat, spicy, or strong-tasting food was avoided while the amount changed. Smaller meals left less stretch in the stomach and could ease nausea [10].
The retatrutide side effects were worst in weeks 1–8. That was true even for the group headed toward 12 mg. Problems eased after the amount stayed level. These were steps inside a watched study, not a personal care plan.